gsk3915393
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 6, 2020 (NCT04604795)
Timeline
Indications
Mechanism of action
TGM2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06625489 | Phase 1 | Oct 3, 2024 | GlaxoSmithKline |
| NCT06317285 | Phase 2 | Apr 4, 2024 | GlaxoSmithKline |
| NCT04604795 | Phase 1 | Nov 6, 2020 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2020 |
1 organizations
Page 1 / 1